Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection
Open Access
- 30 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (12) , e0244500
Abstract
The primary objective of this study was to compare concomitant and hybrid therapy in the first line eradication treatment of Helicobacter pylori infection in Split-Dalmatia County, Croatia, in which clarithromycin resistance is above 20%. The secondary objective of the study was to determine and compare compliance and adverse events rate between these therapeutic protocols. In an open-label, randomised clinical trial 140 patients total with H. pylori infection were randomly assigned to either concomitant (esomeprazole 40 mg, amoxicillin 1 g, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days) or hybrid (esomeprazole 40 mg and amoxicillin 1 g twice daily during 14 days with adding metronidazole 500 mg and clarithromycin 500 mg twice daily, in the last 7 days,) treatment group. Eradication rates for concomitant group and hybrid therapy group were 84.1% (58/69) and 83.1% (59/71) respectively in the intention-to-treat analysis and 96.7% (58/60) and 95.2% (59/62) in per-protocol analysis. There was no significant difference between the groups (ITT analysis: P = 0.878; PP analysis: P = 0.675). Adverse events were more frequent in the concomitant group (33.3% vs 18.3%, P = 0.043). There was no difference among groups regarding compliance rate. Hybrid therapy has similar eradication rate as concomitant therapy, with lower adverse events rate. In the era of increasing antibiotic resistance, eradication regime with less antibiotic’s usage, as hybrid therapy, should be reasonable first line treatment choice for H. pylori infection. Clinical Trials, gov: NCT03572777.Keywords
This publication has 36 references indexed in Scilit:
- The Evolution of Helicobacter Pylori Antibiotics Resistance Over 10 Years in GreeceDigestion, 2014
- Review: Efficacy and Safety of Hybrid Therapy for Helicobacter pylori Infection: A Systematic Review and Meta‐analysisHelicobacter, 2014
- Global burden of gastric cancer attributable toHelicobacterpyloriInternational Journal of Cancer, 2014
- Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized studyJournal of Medical Microbiology, 2014
- Concomitant, sequential, and hybrid therapy for H. pylori eradication: A pilot studyClinics and Research in Hepatology and Gastroenterology, 2013
- Helicobacter pylori research: historical insights and future directionsNature Reviews Gastroenterology & Hepatology, 2013
- Comparison of Hybrid and Sequential Therapies for Helicobacter pylori Eradication in Iran: A Prospective Randomized TrialHelicobacter, 2012
- Time trends of primary antibiotic resistance ofHelicobacter pyloriisolates in Southern CroatiaJournal of Chemotherapy, 2012
- Modified Sequential Helicobacter pylori Therapy: Proton Pump Inhibitor and Amoxicillin for 14 Days with Clarithromycin and Metronidazole added as a Quadruple (Hybrid) Therapy for the Final 7 DaysHelicobacter, 2011
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010